Loading...

    Explore
    • Policy Monitoring
    • Live Policy Feed
    • Billing Codes
    • Healthcare Providers
    • Health Insurance Payers
    • States
    • Service Lines
    • Taxonomy Codes
    Lookup tools
    • Billing Code Lookup
    • CPT Modifier Lookup
    • Provider Taxonomy Code Lookup
    • Healthcare Provider & Facility Lookup
    • Health Insurance Payer Lookup
    • Payer Contact Directory

    Policy & Benchmark Tools

    • Prior Authorization Lookup
    • Coverage Criteria Lookup
    • Timely Filing Lookup
    • Billing Code Reimbursement Rates
    • Payer Comparison Dashboard
    • Facility Comparison Dashboard
    • All tools

    Company

    • About OpenPayer
    • Data Sources
    • Request a Policy / Feedback
    • Trek Health
    OpenPayerby Trek Health
    LinkedInYouTube

    © 2026 Trek Health. All rights reserved.

    OpenPayer is built and maintained by Trek Health.

    v1.0.32
    OpenPayerPolicy UpdatesPharmacy & Specialty DrugsCVS Caremark Amphetamine Prior Auth | OpenPayer
    Ask Trek AI about this page
    CurrentCVS CaremarkPolicy N/A

    Initial Prior Authorization Amphetamines

    Customize your policy alerts

    Sign up for all cvs_caremark policy alerts

    Know when cvs_caremark releases new policies or updates existing guidance.

    Monitor payer policy activity

    Receive email alerts as soon as relevant payer policies are published or updated.

    This policy governs initial prior authorization for prescription amphetamine, amphetamine-dextroamphetamine, dextroamphetamine, lisdexamfetamine, and methamphetamine products, including FDA-approved indications and age-related limitations.

    Policy Summary
    PayerCVS Caremark
    PolicyInitial Prior Authorization Amphetamines
    Policy CodePolicy N/A
    Change TypeNo material change
    Effective DateN/A
    Next Review DateN/A
    Key ActionDocument the ADHD/ADD diagnosis using an appropriate clinical assessment, such as DSM-5 assessment, standardized rating scales, interviews, or questionnaires.
    SourceLink
    POLICY UPDATE CHANGES

    No material clinical or coverage changes in this revision.

    5Drug categories referenced
    6 yearsMinimum age specified
    3Covered clinical indications
    1Weight-loss limitations
    36 months

    OpenPayer is powered by Trek Health's payer performance platform. Trek continuously ingests, validates, and normalizes Transparency in Coverage data alongside payer policies and other commercial payer data to create a structured payer intelligence foundation. OpenPayer uses this foundation to deliver personalized search results, dynamically generated policy pages, and tailored policy monitoring based on each user's payers, specialties, billing codes, and areas of interest. The same intelligence powers broader payer performance workflows, including reimbursement benchmarking, contract evaluation, payer negotiations, and financial decision-making.

    Approval duration

    Coverage Criteria

    Initial ADHD/ADD

    Authorization may be granted when the patient has ADHD/ADD and all criteria are met.

    ADHD/ADD initial authorization

    • Acceptable diagnostic documentation: The diagnosis was evaluated using a complete clinical assessment, DSM-5, standardized rating scales, interviews, or questionnaires.

      At least one appropriate diagnostic method must support the diagnosis.

    • Age-specific behavioral therapy requirement: The patient is older than 5 years; OR the patient is 5 years of age or younger and continues to have symptoms despite evidence-based behavioral therapy.Age 5 years or younger

      Examples include parent training in behavior management and behavioral classroom interventions.

    Initial binge-eating disorder

    Authorization may be granted for moderate to severe BED when the following criterion is met.

    BED initial authorization: The request is for Arynta (lisdexamfetamine) or Vyvanse (lisdexamfetamine) for treatment of moderate to severe binge-eating disorder.Moderate to severe BED

    The drug-specific requirement is mandatory.

    Initial narcolepsy

    Authorization may be granted when the patient has narcolepsy and all criteria are met.

    Narcolepsy initial authorization: The requested drug is prescribed by or in consultation with a sleep specialist, and the diagnosis has been confirmed by a sleep study.Confirmed by sleep study

    Both specialist involvement and sleep-study confirmation are required.

    Continuation ADHD/ADD

    Continuation authorization may be granted when the patient has ADHD/ADD and all criteria are met.

    ADHD/ADD continuation authorization: The patient has achieved or maintained improvement in ADHD/ADD signs and symptoms from baseline, and the patient's need for continued therapy has been assessed within the previous year.Assessment within previous year

    Both clinical response and recent continued-need assessment are required.

    Continuation binge-eating disorder

    Continuation authorization may be granted for moderate to severe BED when all criteria are met.

    BED continuation authorization: The request is for Arynta (lisdexamfetamine) or Vyvanse (lisdexamfetamine); the patient has achieved or maintained improvement in BED symptoms from baseline; and the patient's need for continued therapy has been assessed within the previous year.Assessment within previous year

    All drug, response, and reassessment requirements apply.

    Continuation narcolepsy

    Continuation authorization may be granted when the patient has narcolepsy and the following criterion is met.

    Narcolepsy continuation authorization: The patient has achieved or maintained improvement in daytime sleepiness with narcolepsy from baseline.Improvement or maintenance from baseline

    Clinical response must be documented.

    Narcolepsy

    Authorization may be granted when the patient has a diagnosis of narcolepsy and the following criterion is met.

    Narcolepsy authorization criteria

    • Diagnosis: The patient has a diagnosis of narcolepsy.
    • Clinical response: The patient achieved or maintained improvement in daytime sleepiness with narcolepsy from baseline.Improvement from baseline

    Arynta is not indicated or recommended for weight loss. The safety and effectiveness of Arynta for the treatment of obesity have not been established.

    Vyvanse is not indicated or recommended for weight loss. The safety and effectiveness of Vyvanse for the treatment of obesity have not been established.

    Mydayis is not recommended for pediatric patients 12 years and younger. Xelstrym is not recommended for pediatric patients younger than 6 years, due to higher exposure and increased adverse reactions in younger children.

    Authorization and Documentation Requirements

    Prior Authorization

    Initial ADHD/ADD Authorization

    For initial ADHD/ADD authorization, document the diagnosis through an appropriate clinical assessment and, when the patient is age 5 or younger, document persistent symptoms despite evidence-based behavioral therapy.

    • Diagnosis of ADHD or ADD is appropriately documented.
    • For patients age 5 or younger, symptoms continue despite evidence-based behavioral therapy, such as parent training in behavior management or behavioral classroom interventions.
    Prior Authorization

    Initial BED Authorization

    For initial BED authorization, the requested drug must be Arynta (lisdexamfetamine) or Vyvanse (lisdexamfetamine) and must be prescribed for moderate to severe binge eating disorder.

    • Requested drug: Arynta (lisdexamfetamine) or Vyvanse (lisdexamfetamine).
    • Indication: moderate to severe binge eating disorder (BED).

    Policy Background

    This policy addresses stimulant products used for attention deficit hyperactivity disorder (ADHD) and narcolepsy, as well as moderate to severe binge-eating disorder (BED) for Arynta and Vyvanse. Coverage criteria distinguish initial and continuation therapy and include product-specific pediatric age limitations.

    Key Definitions

    ADHD/ADD
    ConditionAttention-Deficit/Hyperactivity Disorder (ADHD) or Attention Deficit Disorder (ADD)
    Diagnostic requirementThe diagnosis must be appropriately documented through a clinical assessment.
    Acceptable assessment methodsComplete clinical assessment, DSM-5 assessment, standardized rating scales, interviews, or questionnaires.
    Binge-eating disorder (BED)
    ConditionBinge-eating disorder (BED)
    SeverityModerate to severe BED.
    Covered treatment

    Initial Therapy Criteria

    Initial ADHD/ADD

    Initial authorization for ADHD/ADD requires all criteria below.

    ADHD/ADD initial authorization

    • Acceptable diagnostic documentation: The diagnosis was evaluated using a complete clinical assessment, DSM-5, standardized rating scales, interviews, or questionnaires.

      At least one appropriate diagnostic method must support the diagnosis.

    • Age-specific behavioral therapy requirement: The patient is older than 5 years; OR the patient is 5 years of age or younger and continues to have symptoms despite evidence-based behavioral therapy.Age 5 years or younger

      Examples include parent training in behavior management and behavioral classroom interventions.

    Initial binge-eating disorder

    Continuation Therapy Criteria

    Continuation ADHD/ADD

    Continuation authorization for ADHD/ADD requires all criteria below.

    ADHD/ADD continuation authorization: The patient has achieved or maintained improvement in ADHD/ADD signs and symptoms from baseline, and the patient's need for continued therapy has been assessed within the previous year.Assessment within previous year

    Both clinical response and recent continued-need assessment are required.

    Continuation binge-eating disorder

    Continuation authorization for BED requires all criteria below.

    BED continuation authorization: The request is for Arynta (lisdexamfetamine) or Vyvanse (lisdexamfetamine); the patient has achieved or maintained improvement in BED symptoms from baseline; and the patient's need for continued therapy has been assessed within the previous year.Assessment within previous year

    Step Therapy Requirements

    StepRequirementFailure criteria
    1Evidence-based behavioral therapy for patients 5 years of age or younger with ADHD/ADD; therapy must be attempted or ongoing before authorization when symptoms persist.Continued ADHD/ADD symptoms despite participation in evidence-based behavioral therapy.
    Policy Summary
    PayerCVS Caremark
    PolicyInitial Prior Authorization Amphetamines
    Policy CodePolicy N/A
    Change TypeNo material change
    Effective DateN/A
    Next Review DateN/A
    Key ActionDocument the ADHD/ADD diagnosis using an appropriate clinical assessment, such as DSM-5 assessment, standardized rating scales, interviews, or questionnaires.
    SourceLink
    On This Page
    Coverage CriteriaAuthorization and Documentation RequirementsPolicy BackgroundKey DefinitionsInitial Therapy CriteriaContinuation Therapy CriteriaStep Therapy Requirements
    Prior Authorization

    Initial Narcolepsy Authorization

    For initial narcolepsy authorization, confirm the diagnosis with a sleep study and ensure the drug is prescribed by, or in consultation with, a sleep specialist.

    • Requested drug is prescribed by, or in consultation with, a sleep specialist.
    • Narcolepsy diagnosis is confirmed by a sleep study.
    Documentation Required

    Narcolepsy: Document Improved Daytime Sleepiness

    For narcolepsy continuation authorization, document that the patient achieved or maintained improvement in daytime sleepiness from baseline.

    • Improvement in daytime sleepiness with narcolepsy is achieved or maintained from baseline.
    Documentation Required

    Behavioral Therapy Required for Young Children

    For a patient age 5 or younger with ADHD/ADD, document participation in evidence-based behavioral therapy before requesting authorization.

    • Examples include parent training in behavior management (PTBM) and behavioral classroom interventions.
    • Symptoms must continue despite the behavioral therapy.
    Documentation Required

    ADHD/ADD Diagnostic Documentation

    Support the ADHD/ADD diagnosis with an appropriate clinical assessment, such as a complete assessment using DSM-5 criteria, standardized rating scales, and interviews or questionnaires.

    • Document the assessment method used to establish ADHD/ADD.
    Documentation Required

    Document Symptoms Despite Behavioral Therapy

    For patients age 5 or younger, document ongoing ADHD/ADD symptoms despite participation in evidence-based behavioral therapy.

    • Document the behavioral therapy provided and the patient's persistent symptoms.
    • Examples include parent training in behavior management (PTBM) and behavioral classroom interventions.
    Documentation Required

    Narcolepsy Confirmation and Specialist Documentation

    Narcolepsy authorization requires both diagnostic confirmation and specialist involvement. Include the sleep-study documentation and the prescribing sleep specialist's involvement or consultation.

    • Diagnosis confirmed by a sleep study.
    • Prescription written by, or consultation obtained from, a sleep specialist.

    Unsupported block type: prior_auth

    Unsupported block type: billing_rule

    Unsupported block type: denial_risk

    Unsupported block type: denial_risk

    Unsupported block type: denial_risk

    Unsupported block type: denial_risk

    Unsupported block type: denial_risk

    Arynta (lisdexamfetamine) or Vyvanse (lisdexamfetamine).

    Initial authorization for BED requires the following criterion.

    BED initial authorization: The request is for Arynta (lisdexamfetamine) or Vyvanse (lisdexamfetamine) for treatment of moderate to severe binge-eating disorder.Moderate to severe BED

    The drug-specific requirement is mandatory.

    Initial narcolepsy

    Initial authorization for narcolepsy requires all criteria below.

    Narcolepsy initial authorization: The requested drug is prescribed by or in consultation with a sleep specialist, and the diagnosis has been confirmed by a sleep study.Confirmed by sleep study

    Both specialist involvement and sleep-study confirmation are required.

    Narcolepsy

    Authorization may be granted when the patient has a diagnosis of narcolepsy and the following criterion is met.

    Narcolepsy authorization criteria

    • Diagnosis: The patient has a diagnosis of narcolepsy.
    • Clinical response: The patient achieved or maintained improvement in daytime sleepiness with narcolepsy from baseline.Improvement from baseline

    All drug, response, and reassessment requirements apply.

    Continuation narcolepsy

    Continuation authorization for narcolepsy requires the following criterion.

    Narcolepsy continuation authorization: The patient has achieved or maintained improvement in daytime sleepiness with narcolepsy from baseline.Improvement or maintenance from baseline

    Clinical response must be documented.